OncoCyte (NASDAQ:OCX) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of OncoCyte (NASDAQ:OCX) in a report released on Tuesday. The firm issued a sell rating on the stock.

OCX has been the topic of a number of other research reports. Needham & Company LLC lifted their target price on OncoCyte from $3.60 to $4.25 and gave the company a buy rating in a research report on Wednesday, April 24th. Benchmark restated a speculative buy rating and issued a $5.00 target price on shares of OncoCyte in a research report on Monday, April 15th. Finally, Stephens restated an equal weight rating and issued a $4.00 target price on shares of OncoCyte in a research report on Wednesday, April 17th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, OncoCyte presently has a consensus rating of Hold and a consensus target price of $4.06.

OncoCyte Trading Down 1.4 %

Shares of OncoCyte stock opened at $2.49 on Tuesday. OncoCyte has a one year low of $2.08 and a one year high of $6.20. The business’s 50 day moving average price is $2.87 and its 200 day moving average price is $3.01.

Insider Activity at OncoCyte

In other news, major shareholder Broadwood Partners, L.P. acquired 2,420,000 shares of the business’s stock in a transaction that occurred on Thursday, April 11th. The shares were purchased at an average price of $2.92 per share, for a total transaction of $7,066,400.00. Following the acquisition, the insider now owns 4,929,066 shares of the company’s stock, valued at $14,392,872.72. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In related news, Director Andrew Arno bought 33,898 shares of the stock in a transaction that occurred on Thursday, April 11th. The stock was purchased at an average cost of $2.95 per share, with a total value of $99,999.10. Following the purchase, the director now directly owns 69,054 shares of the company’s stock, valued at approximately $203,709.30. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Broadwood Partners, L.P. bought 2,420,000 shares of the stock in a transaction that occurred on Thursday, April 11th. The shares were bought at an average cost of $2.92 per share, with a total value of $7,066,400.00. Following the completion of the purchase, the insider now directly owns 4,929,066 shares in the company, valued at $14,392,872.72. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 2,457,288 shares of company stock worth $7,176,400. 1.94% of the stock is currently owned by company insiders.

OncoCyte Company Profile

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.